Stone Ridge Asset Management LLC bought a new stake in MEDNAX Inc (NYSE:MD) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 29,051 shares of the company’s stock, valued at approximately $1,552,000.
Other hedge funds have also recently made changes to their positions in the company. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of MEDNAX in the third quarter valued at about $103,000. Delta Capital Management LLC purchased a new stake in MEDNAX during the fourth quarter worth about $227,000. Brown Advisory Inc. purchased a new stake in MEDNAX during the fourth quarter worth about $231,000. YHB Investment Advisors Inc. purchased a new stake in MEDNAX during the fourth quarter worth about $235,000. Finally, Shelton Capital Management purchased a new stake in MEDNAX during the fourth quarter worth about $245,000. Institutional investors own 98.53% of the company’s stock.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the business’s stock in a transaction on Tuesday, March 13th. The shares were sold at an average price of $58.35, for a total transaction of $175,050.00. Following the transaction, the insider now directly owns 39,716 shares of the company’s stock, valued at approximately $2,317,428.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.40% of the stock is currently owned by insiders.
A number of equities analysts have weighed in on MD shares. TheStreet upgraded shares of MEDNAX from a “c+” rating to a “b” rating in a research report on Monday, March 12th. Jefferies Group set a $58.00 price objective on shares of MEDNAX and gave the company a “hold” rating in a research report on Thursday, March 15th. Zacks Investment Research lowered shares of MEDNAX from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 21st. Credit Suisse Group began coverage on shares of MEDNAX in a research report on Tuesday, March 27th. They issued a “neutral” rating and a $57.00 price objective for the company. Finally, Robert W. Baird lifted their target price on shares of MEDNAX from $48.00 to $54.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $55.69.
Shares of NYSE MD opened at $54.67 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.60. MEDNAX Inc has a 52 week low of $40.56 and a 52 week high of $68.55. The firm has a market capitalization of $5,178.45, a P/E ratio of 17.36, a PEG ratio of 1.37 and a beta of 0.23.
MEDNAX (NYSE:MD) last issued its earnings results on Thursday, February 8th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.83 by $0.04. The company had revenue of $910.82 million for the quarter, compared to the consensus estimate of $884.55 million. MEDNAX had a net margin of 9.26% and a return on equity of 10.10%. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.00 earnings per share. analysts anticipate that MEDNAX Inc will post 4.02 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “29,051 Shares in MEDNAX Inc (NYSE:MD) Purchased by Stone Ridge Asset Management LLC” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/stone-ridge-asset-management-llc-buys-shares-of-29051-mednax-inc-md.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.